Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

被引：3

作者：

Weinstock, Matt ^{[1
]}

Elavalakanar, Pavania ^{[1
]}

Bright, Susan ^{[1
]}

Ambati, Srikanth R. ^{[2
]}

Brouwer-Visser, Jurriaan ^{[2
]}

Pourpe, Stephane ^{[2
]}

Fiaschi, Nathalie ^{[2
]}

Jankovic, Vladimir ^{[2
]}

Thurston, Gavin ^{[2
]}

Deering, Raquel P. ^{[2
]}

Chaudhry, Aafia ^{[2
]}

Joyce, Robin ^{[1
]}

Arnason, Jon ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Hematol Oncol, Boston, MA 02215 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 03期

关键词：

bispecific antibodies; cellular therapies; clinical trials; non-Hodgkin lymphoma; tumour immunotherapy;

D O I：

10.1111/bjh.18383

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 x CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for >= 2 years following odronextamab. Neither patient experienced Grade >= 3 cytokine release syndrome or Grade >= 3 neurological adverse events during treatment.

引用

页码：366 / 370

页数：5

共 50 条

[41] Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
Denlinger, Nathan
Huang, Ying
Braunstein, Zachary
Sigmund, Audrey
Bajwa, Amneet
Kapoor, Nilesh
Agyeman, Akwasi
Fisher, Scott
Purdin, Zebulun
Neal, Alison
Yucebay, Filiz
Roddy, Julianna
Brammer, Jonathan
William, Basem
Saad, Ayman
Penza, Sam
Voorhees, Timothy
Kittai, Adam
de Lima, Marcos
Vasu, Sumithira
Jaglowski, Samantha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S381 - S382
[42] An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
Xue, Bin
Liu, Yifan
Zhang, Min
Xiao, Gangfeng
Luo, Xiu
Zhou, Lili
Ye, Shiguang
Lu, Yan
Qian, Wenbin
Wang, Li
Li, Ping
Liang, Aibin
CHINESE MEDICAL JOURNAL, 2025, 138 (01) : 108 - 110
[43] Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
Tian, Linyan
Li, Cheng
Sun, Juan
Zhai, Yixin
Wang, Jinhuan
Liu, Su
Jiang, Yanan
Wu, Wenqi
Xing, Donghui
Lv, Yangyang
Guo, Jing
Xu, Hong
Sun, Huimeng
Li, Yuhang
Li, Lanfang
Zhao, Zhigang
FRONTIERS IN IMMUNOLOGY, 2023, 13
[44] Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Parikh, Rahul R.
Milgrom, Sarah A.
Campbell, Belinda A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1152 - 1158
[45] CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
D'Ovidio, Tyler
Ciccolini, Kathryn
Kalac, Matko
Osman, Keren
Steinberg, Amir
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[46] Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis
Kelkar, Amar H.
Cliff, Edward R. Scheffer
Jacobson, Caron A.
Abel, Gregory A.
Dijk, Stijntje W.
Krijkamp, Eline M.
Redd, Robert
Zurko, Joanna C.
Hamadani, Mehdi
Hunink, M. G. Myriam
Cutler, Corey
ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1625 - 1637
[47] Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations
Allred, Jeremy
Bharucha, Kharmen
Ozutemiz, Can
He, Fiona
Janakiram, Murali
Maakaron, Joseph
Carrier, Claire
Grzywacz, Bartosz
Bachanova, Veronika
BONE MARROW TRANSPLANTATION, 2021, 56 (03) : 679 - 682
[48] Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations
Jeremy Allred
Kharmen Bharucha
Can Özütemiz
Fiona He
Murali Janakiram
Joseph Maakaron
Claire Carrier
Bartosz Grzywacz
Veronika Bachanova
Bone Marrow Transplantation, 2021, 56 : 679 - 682
[49] Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Steiner, Raphael E.
Banchs, Jose
Koutroumpakis, Efstratios
Becnel, Melody
Gutierrez, Cristina
Strati, Paolo
Pinnix, Chelsea C.
Feng, Lei
Rondon, Gabriela
Claussen, Catherine
Palaskas, Nicolas
Karimzad, Kaveh
Ahmed, Sairah
Neelapu, Sattva S.
Shpall, Elizabeth
Wang, Michael
Vega, Francisco
Westin, Jason
Nastoupil, Loretta J.
Deswal, Anita
HAEMATOLOGICA, 2022, 107 (07) : 1555 - 1566
[50] Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.
Lin, John
Muffly, Lori S.
Spinner, Michael Alexander
Barnes, James I.
Owens, Douglas K.
Goldhaber-Fiebert, Jeremy D.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →